The latest price target for IN8bio (NASDAQ:INAB) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $8.00 expecting INAB to rise to within 12 months (a possible 2337.54% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for IN8bio (NASDAQ:INAB) was provided by HC Wainwright & Co., and IN8bio maintained their buy rating.

There is no last upgrade for IN8bio

The last downgrade for IN8bio Inc happened on August 12, 2024 when Jones Trading changed their price target from N/A to N/A for IN8bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IN8bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IN8bio was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest IN8bio (INAB) rating was a maintained with a price target of $12.50 to $8.00. The current price IN8bio (INAB) is trading at is $0.33, which is out of the analyst’s predicted range.